Jushi Holdings Inc. (CSE:JUSH, OTCQX:JUSHF) has welcomed the Commonwealth Court of Pennsylvania’s order temporarily halting the Pennsylvania Department of Health’s (DOH) recall of certain vaporized medical marijuana products.
The court granted Medical Marijuana Access & Patient Safety Inc's application to vacate the automatic stay of injunctive relief ordered on June 2 this year.
"On behalf of Pennsylvania’s medical marijuana patient community, we would like to extend our appreciation to the Commonwealth Court for its thoughtful assessment of the facts and circumstances upon which DOH’s February recall of tested, approved medical marijuana vaporization products containing terpenes was based, and for the subsequent orders issued on June 2 and June 15 allowing responsible operators to again make these products accessible to patients,” the company said in a statement.
READ: Jushi Holdings is building out its portfolio of premium cannabis assets as US consumer appetites grow
“In light of the Court’s Orders, impacted products will be back on the shelves of BEYOND/HELLO dispensaries today and the shelves of our partner dispensaries across the Commonwealth in the coming days," it added.
The company noted that the court came to the unambiguous conclusion that DOH had “failed to present any evidence” of potential harm to medical marijuana patients associated with the recalled products.
Under Pennsylvania law, all medical marijuana products, including the recalled vaporization products, are subject to rigorous, redundant safety and quality testing and Department approval before they can be manufactured or dispensed.
“The Court’s June 2 and June 15 Orders are about more than just preserving patient access to tested, approved, and for many patients, effective medical marijuana products – they deliver peace of mind to thousands of Pennsylvanians that health risks cited by the Department could not be substantiated in any way or any extent,” Jim Cacioppo, chief executive officer, chairman, and founder of Jushi Holdings said.
“In fact, the Court noted the Department itself approved the recalled products for patient use following stringent quality and safety testing and found no evidence of a single adverse event related to any recalled product," he added.
Today is a win for medical marijuana patients, their families, and caregivers across the Commonwealth, the company noted.
Jushi is a vertically integrated cannabis company led by an industry-leading management team.
Contact the author at jon.hopkins@proactiveinvestors.com